id,group_id,source,exact,prefix,suffix,anno_type,position_type,start,end,tags,all,origin_tags,comment,user,title,created
zk-cbq0REemfC4MUbKLMhw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,G28-5,nted by an anti-CD40L antibody (,). This may reduce plasma concen,TextQuoteSelector,TextPositionSelector,53245,53250,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:19:19.558024+00:00
zepf5q0YEem6c7dA0195vg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CD40,). Therapeutic targeting of the ,-CD40L axis using humanized anti,TextQuoteSelector,TextPositionSelector,53055,53059,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:09:25.419758+00:00
z5xYLq0VEem31acF3k5z5A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PAR-1,d accelerates the hydrolysis of , (9). PAR-1 and P2Y12 cross-reac,TextQuoteSelector,TextPositionSelector,13654,13659,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:47:59.854471+00:00
yXjYjq0OEemb7m8sjP_NnA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,receptor tyrosine kinases, it interacts with the membrane , (RTKs) of the TAM family (Tyro3,TextQuoteSelector,TextPositionSelector,27103,27128,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:57:43.088818+00:00
xsUhrK0SEemiCC_yAxrF5A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Ac, associated with adenylcyclase (,) down-regulation and decreased ,TextQuoteSelector,TextPositionSelector,15574,15576,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:26:16.408108+00:00
x8-B6NCNEem87-Mem60iDQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,T× synthase,by cyclooxygenase 1 (COX-1) and ,", further amplifies platelet act",TextQuoteSelector,TextPositionSelector,12484,12495,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:04:56.985353+00:00
wqsqCK0XEemJFsspJxV-tA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,cerebral infarction,"64), 1,510 patients with recent ", were randomly assigned to recei,TextQuoteSelector,TextPositionSelector,44558,44577,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:01:57.059942+00:00
wgeTjK0PEemsUAMBTJt2tQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y12,opidogrel regimen in inhibiting ,-dependent platelet aggregation.,TextQuoteSelector,TextPositionSelector,30877,30882,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:04:39.843387+00:00
wUaWOK0OEem_45sOiOwlTQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,RTKs,with receptor tyrosine kinases (,") of the Tyro3, Axl, and MerTK (",TextQuoteSelector,TextPositionSelector,51452,51456,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:57:28.833417+00:00
wExUQq0ZEemSs18eS3ei1A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,intermittent claudication,ible for inclusion if they have , in conjunction with an ankle-br,TextQuoteSelector,TextPositionSelector,50437,50462,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:16:12.065988+00:00
vZzvfq0hEemwUt9otscczQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CYP, activation by cytochrome P450 (,) liver isoenzymes. While the CA,TextQuoteSelector,TextPositionSelector,17930,17933,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:13:23.593000+00:00
ucFABq0UEemSnd9rbp8VMQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombin,"e so-called thrombin receptor), ", activates platelets and smooth ,TextQuoteSelector,TextPositionSelector,13229,13237,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:40:13.617111+00:00
uAWjNK0OEemYHfvxVag__A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,sCD40L,on of the inflammatory markers (, and interleukin 6 and the expre,TextQuoteSelector,TextPositionSelector,26508,26514,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:57:13.814826+00:00
u726cq0REem4Css0djfRlA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gas6 receptors,inactivation of RNA for Gas6 or ,. Antibodies to the carboxy-term,TextQuoteSelector,TextPositionSelector,51959,51973,WS_GP,yes,[WS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:18:48.438945+00:00
tc9bfq0SEemoWnN0Ea8W9A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,adenylcyclase,naling cascades associated with , (Ac) down-regulation and decrea,TextQuoteSelector,TextPositionSelector,15559,15572,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:25:47.991875+00:00
tZJjwNCMEemmiSu-Mrxa_w,3NabqAPM,https://europepmc.org/articles/PMC3231843/,GP,activation of the glycoprotein (,") IIb/IIIa receptor, resulting i",TextQuoteSelector,TextPositionSelector,14857,14859,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T09:57:16.884091+00:00
tUd4-tCNEemsE5uqO_hb5w,3NabqAPM,https://europepmc.org/articles/PMC3231843/, platelet receptor ,rel irreversibly binds the P2Y12,after a two-step activation by c,TextQuoteSelector,TextPositionSelector,17877,17896,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:04:25.807653+00:00
tNWk8K0QEem2VUtCsmgHbA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptors,"latelet activation, and Gαq and ", are involved in this process. T,TextQuoteSelector,TextPositionSelector,13729,13750,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:11:27.376315+00:00
sizD1q0REemb_EPk_GxtRw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,glycoprotein,"atelets (2,3). Upon activation, ", (Gp) IIb/IIIa (αIIbβ3 integrin),TextQuoteSelector,TextPositionSelector,10081,10093,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:18:32.485700+00:00
rwfgAK0WEem33D9M73nWmQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,coronary artery disease,"outcome in ≈4,500 patients with ", (CAD) and PCI. Several methods ,TextQuoteSelector,TextPositionSelector,19471,19494,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:54:14.532414+00:00
rNParq0hEemnaZeNsGilkA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,protein kinase C,platelet aggregation by priming , activation and by inhibiting ad,TextQuoteSelector,TextPositionSelector,53529,53545,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:12:55.220421+00:00
pSGAoq0jEem6iuNHpJ75mg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PI3K,oteinases (MMPs)By potentiating ," activation, MMP-2 amplifies pla",TextQuoteSelector,TextPositionSelector,27323,27327,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:27:01.225398+00:00
pMVF8q0QEemwFiMXmrqnIQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαi-linked ADP receptor," by secreted ADP, acting on the ",. By blocking Gαq via PAR-1 and ,TextQuoteSelector,TextPositionSelector,13872,13895,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:11:00.480455+00:00
p6sN1K0ZEem_t9epL4UiBQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,limb ischemia, previous revascularization for ,. Participants are randomized to,TextQuoteSelector,TextPositionSelector,50548,50561,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:15:30.801692+00:00
ovyd9K0NEemI6ocz3kw8qg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,vis,"t all, these limitations. Vis-à-"," their net clinical benefit, the",TextQuoteSelector,TextPositionSelector,8855,8858,WT_GP,yes,[WT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:49:28.973469+00:00
olTksK0XEem6biNtK0gQVg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CD40 ligand,-selective MMP-2 inhibition.The , (CD40L; CD 154) is a trans-memb,TextQuoteSelector,TextPositionSelector,52745,52756,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:01:02.688774+00:00
oZkVMq0SEem5nrtbabV7EA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ade-nylylcyclase, C activation and by inhibiting ,. The facilitating effects of PG,TextQuoteSelector,TextPositionSelector,53575,53591,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:25:14.065473+00:00
o8FNlK0WEem4IV8A3qOceQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,COX-1,donic acid by cyclooxygenase 1 (,") and T× synthase, further ampli",TextQuoteSelector,TextPositionSelector,12459,12464,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:53:55.657038+00:00
noq9MK0jEem-4ZPTk31sCQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thromboembolism,i-Gas6 antibody lowers platelet , induced by the intravenous inje,TextQuoteSelector,TextPositionSelector,26874,26889,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:26:50.497327+00:00
nNMzBq0iEemZLN9kt78Wog,3NabqAPM,https://europepmc.org/articles/PMC3231843/,atheroma, properties. At the site of the ," rupture, platelet-released T×A2",TextQuoteSelector,TextPositionSelector,12763,12771,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:19:37.821712+00:00
nLW9CK0OEemKkmshs0N0BQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,TAM membrane receptors,xy-terminal LG domains with the ,. Studies indicate an associatio,TextQuoteSelector,TextPositionSelector,51697,51719,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:56:27.995241+00:00
mbSzwq0WEemZdYfAcRkaBA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,fibrinogen,e by promoting the retention of , and thrombospondin on the plate,TextQuoteSelector,TextPositionSelector,14335,14345,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:53:38.848007+00:00
magf4q0PEemxWO_34Fk7uQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y12 receptor,es.DrugMechanismCommentPrasugrel, inhibitionIrreversible inhibiti,TextQuoteSelector,TextPositionSelector,25972,25986,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:03:32.062129+00:00
lY7Peq0XEemaWUNtVfL-6Q,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y12,"rane domain receptors, P2Y1 and ",", to activate platelets. P2Y1 is",TextQuoteSelector,TextPositionSelector,15150,15155,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:00:41.417770+00:00
kdXlwK0OEemYHAfBF95VJg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,TAM, tyrosine kinases (RTKs) of the ," family (Tyro3, Axl, MerTK); thr",TextQuoteSelector,TextPositionSelector,27143,27146,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:56:09.740937+00:00
jXsQlK0PEemTo0v3Ft4XdQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PAD,ic peripheral arterial disease (,"), clopidogrel administered alon",TextQuoteSelector,TextPositionSelector,18142,18145,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:03:11.673475+00:00
iY7xvNCMEemFkOcnjrgKLA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gaq-coupled P2Y1,tReceptor(s)Effect(s)CommentsADP,; Gai-coupled P2Y12P2Y1: shape c,TextQuoteSelector,TextPositionSelector,10558,10574,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T09:56:02.998195+00:00
iBDIqK0XEemqTu-pn1HF-A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαi, activation of both the Gαq and , pathways by ADP is needed for p,TextQuoteSelector,TextPositionSelector,11547,11550,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:00:18.583515+00:00
iA1oLK0QEemoPBOfJ3oCaA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαq-coupled receptor,"o the P2 purinergic family, the ", P2Y1 and the Gαi-coupled recept,TextQuoteSelector,TextPositionSelector,11438,11458,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:10:12.208784+00:00
hj8kQq0OEemI7rtYJ4ilfA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombospondin ,the retention of fibrinogen and ,on the platelet surface. Intrapl,TextQuoteSelector,TextPositionSelector,14350,14365,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:55:50.128661+00:00
gBurWq0REemnO39-ZojpFQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,GpIbα,egation. Thrombin also binds to ," on the surface of platelets, th",TextQuoteSelector,TextPositionSelector,13505,13510,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:17:08.403687+00:00
g6SsXK0iEem2k6_peZWsYQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,cyclooxygenase 1,erated from arachidonic acid by ," (COX-1) and T× synthase, furthe",TextQuoteSelector,TextPositionSelector,12441,12457,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:18:55.860596+00:00
g2mWUq0PEem9gcO5OGruNw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PAR-1 receptor,ular targets. Thrombin binds to ,", which leads to shape change, p",TextQuoteSelector,TextPositionSelector,14694,14708,WS_GP,yes,[WS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:02:54.905541+00:00
fZjPjK0YEemm3U_V8PQy4A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,acute coronary syndromes,nt has only been efficacious in ,". In addition, newer thienopyrid",TextQuoteSelector,TextPositionSelector,54332,54356,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:07:10.654033+00:00
fNQXpK0jEem39p8RZIAebA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,interleukin 6,nflammatory markers (sCD40L and , and the expression of P-selecti,TextQuoteSelector,TextPositionSelector,26519,26532,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:25:53.794309+00:00
fMUFPK0WEem_qSf7WrMKjw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,myocardial infarction," events (total death, non-fatal ",", repeat revascularization, stro",TextQuoteSelector,TextPositionSelector,25709,25730,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:52:50.219162+00:00
evpeOq0iEemiQItE7oDLHA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,cardiovascular disease,r target for pharmacotherapy in ,.In spite of a significant antit,TextQuoteSelector,TextPositionSelector,12170,12192,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:18:41.100684+00:00
ejAjHq0hEemVAePXtav5AA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PLC," shape change, phospholipase C (",") activation, thromboxane A2 (T×",TextQuoteSelector,TextPositionSelector,14756,14759,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:11:30.252362+00:00
eWfO7q0UEemXzRMYYHij-g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombin receptor, terminal domain (the so-called ,"), thrombin activates platelets ",TextQuoteSelector,TextPositionSelector,13209,13226,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:38:25.461432+00:00
e22kNq0SEemZl2NI32Mabw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ADP receptor,irreversible block of the P2Y12 ,. Because of a distinct chemical,TextQuoteSelector,TextPositionSelector,28172,28184,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:24:09.781107+00:00
dT1Jeq0jEemiRacKq69y9Q,3NabqAPM,https://europepmc.org/articles/PMC3231843/,hemorrhagic stroke,"come), and with a lower risk of ", (0.53% versus 2.01%; RR 0.26; 9,TextQuoteSelector,TextPositionSelector,25011,25029,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:25:41.075445+00:00
dGt-uK0PEemnMGs8E6JIng,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PARs,d protease-activated receptors (,) for thrombin: PAR-1 and PAR-4.,TextQuoteSelector,TextPositionSelector,13093,13097,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:02:29.786360+00:00
dFDgitCMEemRZh9v6rQpMQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gai-coupled P2Y12,(s)CommentsADPGaq-coupled P2Y1; ,P2Y1: shape change; P2Y12: aggre,TextQuoteSelector,TextPositionSelector,10576,10593,"WT_DS,GP",no,[WT_DS][GP],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T09:55:27.165487+00:00
byuEgK0YEemazldCfLqowA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombotic disorders,newer strategy for treatment of , in humans (88). Individual blee,TextQuoteSelector,TextPositionSelector,55003,55023,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:06:46.537310+00:00
bdcR8q0jEemnb6v9rBDsxQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PDE3,eting phosphodiesterase type 3 (,") and, then, determining intrace",TextQuoteSelector,TextPositionSelector,24458,24462,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:25:28.624373+00:00
bTN9Nq0iEem39KuMhhneKA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombi, the formation of platelet-rich ," that, occluding the arterial lu",TextQuoteSelector,TextPositionSelector,10333,10340,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:18:18.012055+00:00
aukjQK0PEemY7ev341rHWQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,phosphodiesterase type 3,"lostazol, selectively targeting "," (PDE3) and, then, determining i",TextQuoteSelector,TextPositionSelector,24432,24456,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:02:13.820127+00:00
a9gHOK0WEemodKv3wKpDqQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,sCD40L,"exodomain (soluble CD40 ligand, ",) is released and binds to integ,TextQuoteSelector,TextPositionSelector,52909,52915,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:52:21.843286+00:00
_Q7hvK0XEemlyy8pVO_wlQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gai-coupled receptors,Y12 cross-reaction (via Gαq and ,)Serotonin5HT-2A receptorsShape ,TextQuoteSelector,TextPositionSelector,11060,11081,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:03:35.103826+00:00
_I0Vjq0lEemssVshMzPjEQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,liver dysfunction,ducers as well as a significant , may be of concern for its use (,TextQuoteSelector,TextPositionSelector,37444,37461,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:43:47.092504+00:00
_8N76K0hEemUDe-D9q0Ywg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Tyro3, tyrosine kinases (RTKs) of the ,", Axl, and MerTK (TAM) family, G",TextQuoteSelector,TextPositionSelector,51465,51470,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:15:14.524665+00:00
Zr1lMq0QEemXtacbo3FqYA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gβi,. By blocking Gαq via PAR-1 and ," via P2Y12, combined inhibition ",TextQuoteSelector,TextPositionSelector,13927,13930,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:09:16.138061+00:00
ZaNGDq0jEemiQwPrm5-KOw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,vasodilator-stimulated phosphoprotein,4.2% of patients (36).Whereas a , (VASP)-tailored clopidogrel loa,TextQuoteSelector,TextPositionSelector,23255,23292,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:25:14.990290+00:00
ZYb9hK0XEemZS1sBxovq_A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P-selectin,rleukin 6 and the expression of ,"), orally activeSarpogrelateSele",TextQuoteSelector,TextPositionSelector,26555,26565,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:59:20.608739+00:00
YLTTEq0SEemU1_fmIOJdPA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ADP-receptor,y of agonists in an aspirin- or , antagonist-independent fashion ,TextQuoteSelector,TextPositionSelector,52482,52494,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:23:25.182480+00:00
Xpncbq0aEemXO8-3rXCwoQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PAR-4, (PARs) for thrombin: PAR-1 and ,. By binding the hirudin-like ex,TextQuoteSelector,TextPositionSelector,13123,13128,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:20:37.758842+00:00
XYWgHK0OEemSditzIOr6qQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent Gla,"Tyro3, Axl, MerTK); through its ", module it interacts with phosph,TextQuoteSelector,TextPositionSelector,27187,27210,WS_GP,yes,[WS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:54:41.558090+00:00
XA6gYq0YEem2d9uqodbk3A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,humans,ment of thrombotic disorders in ," (88). Individual bleeding risk,",TextQuoteSelector,TextPositionSelector,55027,55033,CRT_OG,no,CRT_OG,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:06:14.304660+00:00
X4JZ5q0TEemXx49aHJQsoQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,(COX)-l,let aggregation. Cyclooxygenase , catalyzes the production of T×A,TextQuoteSelector,TextPositionSelector,14926,14933,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:30:32.525253+00:00
WszJrq0iEemSxfvu9ySB1w,3NabqAPM,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,mplications of atherosclerosis (," (ACS), acute myocardial infarct",TextQuoteSelector,TextPositionSelector,9585,9608,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:17:47.171298+00:00
WmaYBK0ZEemxhXuAhsWRPw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,protein S,as a 44% sequence homology with ,", it does not show any anticoagu",TextQuoteSelector,TextPositionSelector,51306,51315,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:13:20.982943+00:00
WGsmgq0jEemonLek3vt4jA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ABCB1,ulating clopidogrel absorption (,) have been associated with a hi,TextQuoteSelector,TextPositionSelector,21405,21410,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:24:52.743688+00:00
V-lXnq0SEem2XZdnDZfw0w,3NabqAPM,https://europepmc.org/articles/PMC3231843/,AMI,"), acute myocardial infarction (","), ischemic stroke) are the lead",TextQuoteSelector,TextPositionSelector,9645,9648,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:23:10.458465+00:00
V-kSzK0aEem_uocAdSIViQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ischemic stroke,"te myocardial infarction (AMI), ",) are the leading causes of morb,TextQuoteSelector,TextPositionSelector,9651,9666,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:20:26.416363+00:00
UdJwxq0REemPUktGKfZS8A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,GpIIb/ Ilia receptor,"el, cangrelor, ticagrelor), and "," antagonists (abciximab, eptifib",TextQuoteSelector,TextPositionSelector,15950,15970,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:15:50.761172+00:00
UQOy6K0YEem9uV94vJddQQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,bleeding tendency,ed with a worse safety (greater ,).A concerted effort that takes ,TextQuoteSelector,TextPositionSelector,55222,55239,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:05:55.835465+00:00
UKWLiK0mEeml6bd4oUnCuA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,hyperuricemia,d with caution in patients with ,", bradyar-rhythmias without pace",TextQuoteSelector,TextPositionSelector,42181,42194,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:46:07.934234+00:00
TynWXq0UEemXyzd3ds7qyA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,stroke,"causes, non-fatal MI, non-fatal ",) occurred in 643 patients (9.9%,TextQuoteSelector,TextPositionSelector,31693,31699,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:37:14.735671+00:00
TnwWEtCNEemKnitN2LLnKA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y1,"d P2Y12, to activate platelets. ", is coupled to Gαq and G12. Gαq ,TextQuoteSelector,TextPositionSelector,15194,15198,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:01:33.530021+00:00
Tat73K0WEem9rwcWTx51vA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CD40L,P-2 inhibition.The CD40 ligand (,; CD 154) is a trans-membrane pr,TextQuoteSelector,TextPositionSelector,52758,52763,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:51:31.037474+00:00
SnHHDK0PEem-qbeXfa-OBA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,phosphoinositide 3-kinase,"rylated VASP, and activation of ", are blocked. The net result is ,TextQuoteSelector,TextPositionSelector,36650,36675,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:01:19.478008+00:00
SepYvK0jEemZL3fspwAr5A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,hypercoagulable states,"iabetes mellitus, inflammation, ",", low fibrinolytic potential), h",TextQuoteSelector,TextPositionSelector,20013,20035,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:24:28.404347+00:00
S4crNq0aEem9xSdM4dH9_Q,3NabqAPM,https://europepmc.org/articles/PMC3231843/,acute myocardial infarction,o acute ischemic complications (,", ischemic stroke). In view of t",TextQuoteSelector,TextPositionSelector,8279,8306,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:20:05.483181+00:00
S1i3RK0iEem5zp8Wn4mW5g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,stroke,ers of serious vascular events (,", acute coronary syndrome, or va",TextQuoteSelector,TextPositionSelector,44816,44822,WS_DS,no,WS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:17:21.261266+00:00
RQAhvtCNEemQtW_kddJdMA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y1,-coupled P2Y1; Gai-coupled P2Y12,: shape change; P2Y12: aggregati,TextQuoteSelector,TextPositionSelector,10593,10597,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:01:17.465705+00:00
R2rg9K0SEem_-ntxPnsTrg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,atherosclerotic disease,nt of patients with established , receiving standard therapy (up ,TextQuoteSelector,TextPositionSelector,50146,50169,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:22:42.577806+00:00
QFLO5K0mEemUIM-PZ6MqYw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,hypotension,"ng ticagrelor. Dyspnea, nausea, ",", and asymptomatic ventricular p",TextQuoteSelector,TextPositionSelector,41956,41967,WT_DS,no,[WT_DS],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:45:40.784108+00:00
QAoO_q0aEemYUPt8txnFFg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CYP2C19,of or a reduced function in the , gene had a higher than normal o,TextQuoteSelector,TextPositionSelector,21173,21180,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:19:46.291117+00:00
PSlViK0PEemoYG-oVuAqIQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,phosphoinositide-3 kinase,"77). Active MMP-2, potentiating "," activation, amplifies platelet ",TextQuoteSelector,TextPositionSelector,52362,52387,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:00:57.094590+00:00
PQPxbq0SEem_-MNFEPgIwA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CAD,s with coronary artery disease (,) and PCI. Several methods were ,TextQuoteSelector,TextPositionSelector,19496,19499,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:22:25.100399+00:00
PHKzdK0TEemiDBeZW0mKkA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,(CYP) 2C19,notyping of the cytochrome P450 ," (*1,*2,*3,*4,*5,*6,*7,*8,*17) w",TextQuoteSelector,TextPositionSelector,38125,38135,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:29:33.724447+00:00
P7A5vK0iEeml2IskkVzkrQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,acute coronary syndrome,"erious vascular events (stroke, ",", or vascular death) were second",TextQuoteSelector,TextPositionSelector,44824,44847,WS_DS,no,WS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:17:01.732879+00:00
OhNolK0YEemZsPNa_BYc4g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,cytochrome P450,nce dose) the genotyping of the ," (CYP) 2C19 (*1,*2,*3,*4,*5,*6,*",TextQuoteSelector,TextPositionSelector,38109,38124,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:05:17.219920+00:00
N4Z8Rq0jEem39Xvb9LR42w,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombotic thrombocytopenic purpura,"utropenia, aplastic anemia, and ", are the main limitations for a ,TextQuoteSelector,TextPositionSelector,17687,17722,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:23:57.581114+00:00
MmDIvq0WEem3ydvKMr6Bhg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,MMP-2,m upon aggregation (77). Active ,", potentiating phosphoinositide-",TextQuoteSelector,TextPositionSelector,52342,52347,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:50:45.538111+00:00
LowFJq0YEemrwFv5GztWVw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Human,ession of atherosclerosis (76). , platelets contain MMP-2 in thei,TextQuoteSelector,TextPositionSelector,52248,52253,CRT_OG,yes,[CRT_OG][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:04:58.108670+00:00
LcOE0q0aEemfLT8lHZMllw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CER,treatment of CAD patients. TRA* ," (71) is a prospective, randomiz",TextQuoteSelector,TextPositionSelector,49502,49505,WT_GP,no,[WT_GP],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:19:15.781764+00:00
LWTHXq0PEemoJA9xM3Gw2A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y12 platelet receptor,pidogrel irreversibly binds the , after a two-step activation by ,TextQuoteSelector,TextPositionSelector,17858,17881,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:00:30.661915+00:00
L2tukq0SEemob_PVk-m7JA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CD 154, aggregationCD40 ligand (CD40L; ,)On activated platelets an exodo,TextQuoteSelector,TextPositionSelector,27607,27613,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:22:02.360062+00:00
KwK6Nq0XEemRjZ_BKXI7mw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ischemia-reperfusion injury,ve effects in hearts exposed to , (79). MMP-2 gene-silencing tech,TextQuoteSelector,TextPositionSelector,52613,52640,WS_DS,no,WS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:57:42.413877+00:00
KMl5Qq0jEeml3Vv8Ei2BIA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,aplastic anemia,"on (16). Diarrhea, neutropenia, ",", and thrombotic thrombocytopeni",TextQuoteSelector,TextPositionSelector,17666,17681,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:23:32.692375+00:00
K-9VLq0ZEemwPz9YtDoMkg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,growth factor,oagulant activity (74). Being a ,"-like molecule, as it interacts ",TextQuoteSelector,TextPositionSelector,51375,51388,WT_GP,no,[WT_GP],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:12:03.100528+00:00
Jv0cJq0QEem9hiPXY6aDhw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,integrin αIIbβ3,CD40L) is released and binds to ," on activated platelets, thus pr",TextQuoteSelector,TextPositionSelector,52942,52957,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:07:29.340881+00:00
JqE0xq0OEem2RT84nYDEfw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Vitamin K-dependent protein, (growth arrest-specific gene 6),; a polyclonal anti-Gas6 antibod,TextQuoteSelector,TextPositionSelector,26797,26824,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:53:09.779566+00:00
Jg2j2K0SEemRcVfV-8CVvA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,collagen,ectivelyDZ-697bDZ-697b inhibits , and ristocetin-mediated platele,TextQuoteSelector,TextPositionSelector,45471,45479,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:21:46.793958+00:00
JYD3oq0TEemwIedNWL8qiQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,(Gp) IIb,". Upon activation, glycoprotein ",/IIIa (αIIbβ3 integrin) mediates,TextQuoteSelector,TextPositionSelector,10094,10102,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:28:55.172112+00:00
JGpavtCNEemOD89eIkDSTw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,injury ,latelet recruitment at sites of ,(3). It may also play a pro-coag,TextQuoteSelector,TextPositionSelector,14269,14276,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:00:22.652040+00:00
IpsJiK0YEemcE_8mK7nUZw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,5HT-2A,lective inhibitor of serotonin (,) platelet receptorsOrally activ,TextQuoteSelector,TextPositionSelector,26627,26633,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:04:38.104072+00:00
HctiUK0mEem97-tapQzcIw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,intracranial bleedings," 3.8%; P=0.03), including fatal ",", were detected in subjects on t",TextQuoteSelector,TextPositionSelector,41313,41335,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:44:42.692405+00:00
Gf7b1K0SEemlr3eZK2AhGA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Cyclooxygenase,sustained platelet aggregation. , (COX)-l catalyzes the productio,TextQuoteSelector,TextPositionSelector,14911,14925,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:21:26.508263+00:00
F_3BvK0QEemZWEvhghya5A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Matrix metalloproteinases,tidylserine-containing membranes, (MMPs)By potentiating PI3K acti,TextQuoteSelector,TextPositionSelector,27275,27300,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:07:04.315109+00:00
FJ46-q0WEemwMvOBKAINZA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαq,1 and P2Y12 cross-reaction (via , and Gai-coupled receptors)Serot,TextQuoteSelector,TextPositionSelector,11052,11055,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:49:55.650353+00:00
F1sqEq0OEemI7IPyf1nqtA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,vitamin K-dependent proteins,"e 6), a member of the family of ",", is stored in platelet α granul",TextQuoteSelector,TextPositionSelector,51160,51188,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:52:44.269913+00:00
F-7nlK0XEemZR799-baGCg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ischemia,"I, silent AMI, severe recurrent ",", stroke, and death. However, th",TextQuoteSelector,TextPositionSelector,39252,39260,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:57:10.451663+00:00
DoS_sK0PEemxUxup8-_vrQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,platelet receptors,inhibitor of serotonin (5HT-2A) ,Orally activeDZ-697bInhibits col,TextQuoteSelector,TextPositionSelector,26635,26653,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:59:38.791331+00:00
Dlq7Kq0jEemadCOQEtrE2w,3NabqAPM,https://europepmc.org/articles/PMC3231843/,neutropenia,"nt implantation (16). Diarrhea, ",", aplastic anemia, and thromboti",TextQuoteSelector,TextPositionSelector,17653,17664,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:22:48.528092+00:00
Dj6pxq0ZEemKv3sZLcB0_A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,trans-membrane protein,D40 ligand (CD40L; CD 154) is a , expressed on the surface of act,TextQuoteSelector,TextPositionSelector,52778,52800,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:11:13.215759+00:00
Dgldcq0SEemlrh8_cvl8cA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,cyclo-oxygenase,show that platelets with intact , activity can be detected into t,TextQuoteSelector,TextPositionSelector,21930,21945,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:21:06.606469+00:00
DXRlNK0QEem_5kvidOzEJQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,MerTK,"s (RTKs) of the Tyro3, Axl, and "," (TAM) family, Gas6 employs a un",TextQuoteSelector,TextPositionSelector,51481,51486,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:06:46.156316+00:00
D81qqK0OEemRYI9lAOOyJQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,αIIbβ3 integrin,"on, glycoprotein (Gp) IIb/IIIa (",) mediates platelet aggregation ,TextQuoteSelector,TextPositionSelector,10109,10124,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:52:31.214479+00:00
CfNvsq0REem4BG-qm1I1IQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,G-protein-coupled protease-activated receptors,telets express two cell surface , (PARs) for thrombin: PAR-1 and ,TextQuoteSelector,TextPositionSelector,13045,13091,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:13:50.170519+00:00
CeJTiK0iEemRrI86PjDQhA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Axl,"RTKs) of the TAM family (Tyro3, ",", MerTK); through its vitamin K-",TextQuoteSelector,TextPositionSelector,27162,27165,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:15:31.415533+00:00
BGJVaq0jEemK2FeIG_qy3g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,purinergic receptor,action of ADP with its platelet , and to determine the inhibition,TextQuoteSelector,TextPositionSelector,17201,17220,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:22:31.682801+00:00
AW1uUK0SEem2XLM2a7LrnQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,CYP3A4,"er hand, the concomitant use of ", inhibitors/inducers as well as ,TextQuoteSelector,TextPositionSelector,37392,37398,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:20:45.253400+00:00
AL0-Bq0QEemRZg9jzboTWA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,MMPs,ranesMatrix metalloproteinases (,)By potentiating PI3K activation,TextQuoteSelector,TextPositionSelector,27302,27306,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:06:25.023706+00:00
AGvUKq0REemlm08TAFZOFw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,growth arrest-specific gene 6,harmacological strategies.Gas6 (,"), a member of the family of vit",TextQuoteSelector,TextPositionSelector,51102,51131,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:13:34.065664+00:00
9Q_SGq0lEem6lQt1nlWYQw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,kidney failure,no dose adjustment is needed in ,". On the other hand, the concomi",TextQuoteSelector,TextPositionSelector,37334,37348,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:43:34.539348+00:00
9Ne5-q0iEeml3PvXqdEg7A,3NabqAPM,https://europepmc.org/articles/PMC3231843/,PKC,([Ca+2]i) and protein kinase C (,") activation, leading to GP IIb/",TextQuoteSelector,TextPositionSelector,15370,15373,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:22:05.499220+00:00
9LaZHq0OEemI70dDelzVRw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,5-HT platelet receptors,ate is a selective inhibitor of ,". In the S-ACCESS trial (64), 1,",TextQuoteSelector,TextPositionSelector,44478,44501,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:58:55.648287+00:00
960pAq0jEemZbQuvrSVaTA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,intracranial hemorrhage,being associated with increased ,"), in elderly patients (aged ≥ 7",TextQuoteSelector,TextPositionSelector,34282,34305,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:29:19.911920+00:00
8cYiCK0REemoVy8BEXwzCg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,diabetes mellitus,oncomitant clinical conditions (,", inflammation, hypercoagulable ",TextQuoteSelector,TextPositionSelector,19980,19997,WS_DS,no,WS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:20:19.029020+00:00
7hfJTq0XEemRlWfmA1D1TQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gai,(s)CommentsADPGaq-coupled P2Y1; ,-coupled P2Y12P2Y1: shape change,TextQuoteSelector,TextPositionSelector,10562,10565,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:03:09.888471+00:00
7XYEtK0iEem-4CvdYxWpFA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,phospholipase C,"r, which leads to shape change, "," (PLC) activation, thromboxane A",TextQuoteSelector,TextPositionSelector,14739,14754,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:21:53.377374+00:00
74rJsK0OEemappcgMxK8TQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,renal dysfunction,"(e.g. elderly, low body-weight, ",) and avoided in patients with h,TextQuoteSelector,TextPositionSelector,42316,42333,MIS_DS,no,MIS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:58:46.744944+00:00
6lUVdK0lEem3_29_VA2Wyw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,t-PA,) in combination with half-dose ,. A 60-min coronary patency simi,TextQuoteSelector,TextPositionSelector,35699,35703,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:43:16.470960+00:00
6Ho4aq0REemoVjuYWQOjUA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,fibrin,hout affecting thrombin-induced , production. Phase I study data ,TextQuoteSelector,TextPositionSelector,47263,47269,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:20:03.333151+00:00
6H5prK0hEemsm8-_imw0QQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,diabetic angiopathy, not effective in patients with ,", presumably because these patie",TextQuoteSelector,TextPositionSelector,22297,22316,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:14:35.384986+00:00
5cVWZK0VEemKtIuoe2hT_g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gas6,dent protein; a polyclonal anti-, antibody lowers platelet thromb,TextQuoteSelector,TextPositionSelector,26844,26848,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:48:36.768429+00:00
5XeruK0jEemonuM9S1sGdA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,unstable angina, found both among patients with , and non-STEMI and STEMI subject,TextQuoteSelector,TextPositionSelector,32216,32231,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:28:49.377029+00:00
5WeNrK0NEemjjDupIXYHDw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,αIIbβ3 integrin receptor,cretion; P-selectin expression; ,; platelet activationPAR-1 and P,TextQuoteSelector,TextPositionSelector,10971,10995,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T05:51:20.330387+00:00
5OsfbNCNEemSwFOwfQLgiw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,TPb ,"5-HT, T×A2, and thrombinT×A2TPa;",(secondary)Shape change; platele,TextQuoteSelector,TextPositionSelector,10702,10706,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:05:45.809120+00:00
543Vnq0ZEemohwfDKDjtVw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,peripheral artery disease,ime of inclusion. Patients with , (PAD) are eligible for inclusio,TextQuoteSelector,TextPositionSelector,50365,50390,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:17:17.895676+00:00
4aPT3q0WEemPcL9Pt-GWYw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,thrombotic,"of higher doses of clopidogrel, ", events still occur in 4.2% of p,TextQuoteSelector,TextPositionSelector,23190,23200,WT_DS,yes,[WT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:55:39.323221+00:00
4_7EPq0iEemPhq-VIk8i7g,3NabqAPM,https://europepmc.org/articles/PMC3231843/,hirudin,PAR-1 and PAR-4. By binding the ,-like extracellular amino termin,TextQuoteSelector,TextPositionSelector,13145,13152,CRT_GP,no,CRT_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:21:37.420515+00:00
4UA4jK0SEemZZJvtPKjMWg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,ACS,rosis (acute coronary syndrome (,"), acute myocardial infarction (",TextQuoteSelector,TextPositionSelector,9610,9613,MIS_DS,yes,[MIS_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:27:00.952802+00:00
3PlEvtCNEemsFItq7HmWIg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,TPa," by 5-HT, T×A2, and thrombinT×A2",;TPb (secondary)Shape change; pl,TextQuoteSelector,TextPositionSelector,10698,10701,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:05:32.510234+00:00
3FqDrq0hEemoaq91ug6llg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,diabetes,it being found in patients with ,", with coronary stents, or with ",TextQuoteSelector,TextPositionSelector,34801,34809,CRT_DS,no,CRT_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T08:14:15.094098+00:00
3CeyQK0REemU1d-OAn_D8Q,3NabqAPM,https://europepmc.org/articles/PMC3231843/,G12,transient platelet aggregation. , mediates platelet shape change.,TextQuoteSelector,TextPositionSelector,15457,15460,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:19:42.752662+00:00
35B_sq0QEemXtm9PZgKGHg,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Gαi-coupled receptor,q-coupled receptor P2Y1 and the , P2Y12. The concomitant activati,TextQuoteSelector,TextPositionSelector,11472,11492,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:12:38.913318+00:00
2HijAK0dEemZi6sAbsyplQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,myocardial infarction,",000 subjects with a history of ",", will evaluate the efficacy of ",TextQuoteSelector,TextPositionSelector,43720,43741,WS_DS,no,WS_DS,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:45:30.696163+00:00
1J-gyq0PEem_5cNh7ZbMFQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,P2Y1 receptor,ousTicagrelorP2Y12 and (partly) , inhibitionReversible inhibition,TextQuoteSelector,TextPositionSelector,26180,26193,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:05:11.191129+00:00
1CT0HtCNEemjaPfksu19jg,3NabqAPM,https://europepmc.org/articles/PMC3231843/, tissue plasminogen activator,"(280 μg/kg/min) alone, full-dose"," (t-PA) alone, or cangrelor (35,",TextQuoteSelector,TextPositionSelector,35598,35627,WS_GP,no,WS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T10:05:17.704803+00:00
15YQ1NCMEemme7N8doYbCQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,GP IIb," C (PKC) activation, leading to ",/IIIa activation and transient p,TextQuoteSelector,TextPositionSelector,15412,15418,MIS_GP,yes,[MIS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-09-06T09:58:13.852876+00:00
0l_riK0WEemKt7szsMBVJw,3NabqAPM,https://europepmc.org/articles/PMC3231843/,VASP,ator-stimulated phosphoprotein (,)-tailored clopidogrel loading d,TextQuoteSelector,TextPositionSelector,23294,23298,CRT_GP,yes,[CRT_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:55:13.841301+00:00
09QHAK0XEemm3JtwAiwIcQ,3NabqAPM,https://europepmc.org/articles/PMC3231843/,atherosclerosis,tic (ischemic) complications of ," (acute coronary syndrome (ACS),",TextQuoteSelector,TextPositionSelector,9568,9583,CRT_DS,yes,[CRT_DS][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:02:25.725189+00:00
-mA6Hq0YEemRmh-vQoqoWA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,Transmembrane protein ,and blunting platelet reactivity,expressed on the surface of acti,TextQuoteSelector,TextPositionSelector,27792,27814,MIS_GP,no,MIS_GP,,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T07:10:39.888265+00:00
-YQ0NK0SEemPXa9uPFh7qA,3NabqAPM,https://europepmc.org/articles/PMC3231843/,5HT-2A receptors,constrictor agent that binds to , and amplifies the platelet resp,TextQuoteSelector,TextPositionSelector,14127,14143,WS_GP,yes,[WS_GP][ALL],,acct:vaishnavijpai@hypothes.is,Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention.,2019-07-23T06:27:41.494950+00:00
